(VIANEWS) – Greenland Technologies Holding Corporation (GTEC), Interactive Brokers Group (IBKR), Rexford Industrial Realty (REXR) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Greenland Technologies Holding Corporation (GTEC)
34.2% sales growth and 8.31% return on equity
Greenland Technologies Holding Corporation, through its subsidiaries, develops and manufactures transmission and drivetrain systems for material handling machineries and electric vehicles, and electric industrial vehicles in the People's Republic of China and internationally. The company offers transmission products for forklift trucks that are used in manufacturing and logistic applications, such as factories, workshops, warehouses, fulfillment centers, shipyards, and seaports. It also develops robotic cargo carriers. The company was founded in 2006 and is based in Hangzhou, the People's Republic of China.
Earnings Per Share
As for profitability, Greenland Technologies Holding Corporation has a trailing twelve months EPS of $0.29.
PE Ratio
Greenland Technologies Holding Corporation has a trailing twelve months price to earnings ratio of 10.21. Meaning, the purchaser of the share is investing $10.21 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.31%.
2. Interactive Brokers Group (IBKR)
18.3% sales growth and 20.78% return on equity
Interactive Brokers Group, Inc. operates as an automated electronic broker worldwide. The company specializes in routing, executing, and processing trades in stocks, options, futures, foreign exchange instruments, bonds, mutual funds, exchange traded funds (ETFs), metals, and cryptocurrencies. It also custodies and services accounts for hedge and mutual funds, ETFs, registered investment advisors, proprietary trading groups, introducing brokers, and individual investors. In addition, it offers custody, prime brokerage, securities, and margin lending services. The company serves institutional and individual customers through approximately 150 electronic exchanges and market centers. Interactive Brokers Group, Inc. was founded in 1977 and is headquartered in Greenwich, Connecticut.
Earnings Per Share
As for profitability, Interactive Brokers Group has a trailing twelve months EPS of $2.84.
PE Ratio
Interactive Brokers Group has a trailing twelve months price to earnings ratio of 30.02. Meaning, the purchaser of the share is investing $30.02 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.78%.
Moving Average
Interactive Brokers Group’s worth is under its 50-day moving average of $90.22 and above its 200-day moving average of $83.18.
Revenue Growth
Year-on-year quarterly revenue growth grew by 48.8%, now sitting on 3.9B for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Interactive Brokers Group’s EBITDA is 23.94.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Aug 30, 2023, the estimated forward annual dividend rate is 0.4 and the estimated forward annual dividend yield is 0.47%.
3. Rexford Industrial Realty (REXR)
18.2% sales growth and 3.1% return on equity
Rexford Industrial, a real estate investment trust focused on owning and operating industrial properties throughout Southern California infill markets, owns 232 properties with approximately 27.9 million rentable square feet and manages an additional 20 properties with approximately 1.0 million rentable square feet.
Earnings Per Share
As for profitability, Rexford Industrial Realty has a trailing twelve months EPS of $0.98.
PE Ratio
Rexford Industrial Realty has a trailing twelve months price to earnings ratio of 50. Meaning, the purchaser of the share is investing $50 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.1%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Sep 27, 2023, the estimated forward annual dividend rate is 1.52 and the estimated forward annual dividend yield is 3.07%.
Volume
Today’s last reported volume for Rexford Industrial Realty is 489274 which is 61.96% below its average volume of 1286510.
Yearly Top and Bottom Value
Rexford Industrial Realty’s stock is valued at $49.00 at 11:22 EST, way below its 52-week high of $66.71 and higher than its 52-week low of $46.29.
Sales Growth
Rexford Industrial Realty’s sales growth is 27.1% for the present quarter and 18.2% for the next.
4. Fidus Investment Corporation (FDUS)
14.5% sales growth and 8.8% return on equity
Fidus Investment Corporation is a business development company. It specializing in leveraged buyouts, refinancings, change of ownership transactions, recapitalizations, strategic acquisitions, mezzanine, growth capital, business expansion, lower middle market investments, debt investments, subordinated and second lien loans, senior secured and unitranche debt, preferred equity, warrants, subordinated debt, senior subordinated notes, junior secured loans, and unitranche loans. It does not invest in turnarounds or distressed situations. The fund prefers to invest in aerospace and defense, business services, consumer products and services including retail, food, and beverage, healthcare products and services, industrial products and services, information technology services, niche manufacturing, transportation and logistics, and value-added distribution sectors. It seeks to invest in companies based in United States. The fund typically invests between $5 million and $15 million per transaction in companies with annual revenues between $10 million and $150 million and an annual EBITDA between $3 million and $20 million, but it can occasionally invest in larger or smaller companies. It seeks to acquire minority equity stakes and board observation rights in conjunction with its investments.
Earnings Per Share
As for profitability, Fidus Investment Corporation has a trailing twelve months EPS of $1.72.
PE Ratio
Fidus Investment Corporation has a trailing twelve months price to earnings ratio of 10.62. Meaning, the purchaser of the share is investing $10.62 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.8%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 44.5%, now sitting on 112.08M for the twelve trailing months.
5. Entergy Louisiana, LLC First Mortgage Bonds, 5.875% (ELA)
13.2% sales growth and 32.75% return on equity
Envela Corporation, together with its subsidiaries, primarily buys and sells jewelry and bullion products to individual consumers, dealers, Fortune 500 companies, municipalities, school districts, and other organizations in the United States. It offers jewelry and fine-watch products, including bridal jewelry, fashion jewelry, custom-made jewelry, diamonds, and other gemstones, as well as watches and jewelry components. The company also buys and sells various forms of gold, silver, platinum, and palladium products, including United States and other government coins, private mint medallions, art bars, and trade unit bars; and numismatic items, such as rare coins, currency, medals, tokens, and other collectibles, as well as provides jewelry and watches repair services. In addition, it offers end-of-life electronics recycling services; disposal transportation and product tracking services; IT-asset disposition services, including compliance and data sanitization services; and services to companies in the areas of software upgrades, and hardware or networking capabilities, as well as moving to cloud services. As of December 31, 2021, Envela Corporation marketed its products and services through six retail locations under the Dallas Gold & Silver Exchange name; and one retail location under the Charleston Gold & Diamond Exchange name, as well as through cgdeinc.com, dgse.com, echoenvironmental.com, ITADUSA.com, availrecovery.com, and teladvance.com e-commerce sites. The company was formerly known as DGSE Companies, Inc. and changed its name to Envela Corporation in December 2019. Envela Corporation was incorporated in 1965 and is headquartered in Irving, Texas.
Earnings Per Share
As for profitability, Entergy Louisiana, LLC First Mortgage Bonds, 5.875% has a trailing twelve months EPS of $0.49.
PE Ratio
Entergy Louisiana, LLC First Mortgage Bonds, 5.875% has a trailing twelve months price to earnings ratio of 9.02. Meaning, the purchaser of the share is investing $9.02 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 32.75%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Entergy Louisiana, LLC First Mortgage Bonds, 5.875%’s EBITDA is 77.91.
Sales Growth
Entergy Louisiana, LLC First Mortgage Bonds, 5.875%’s sales growth is 14.5% for the current quarter and 13.2% for the next.
Volume
Today’s last reported volume for Entergy Louisiana, LLC First Mortgage Bonds, 5.875% is 13302 which is 69.19% below its average volume of 43176.
6. Tetra Technologies (TTI)
11.2% sales growth and 18.43% return on equity
TETRA Technologies, Inc., together with its subsidiaries, operates as an energy services and solutions company. It operates through two segments, Completion Fluids & Products Division and Water & Flowback Services. The Completion Fluids & Products segment manufactures and markets clear brine fluids, additives, and associated products and services to the oil and gas industry for use in well drilling, completion, and workover operations in the United States, as well as in Latin America, Europe, Asia, the Middle East, and Africa. This segment also markets liquid and dry calcium chloride products; and TETRA PureFlow ultra-pure zinc bromide to battery technology companies. The Water & Flowback Services segment provides water management services for onshore oil and gas operators. This segment also offers frac flowback, production well testing, and other associated services in oil and gas producing regions in the United States and Mexico, as well as in various basins in Latin America, Africa, Europe, and the Middle East. The company was incorporated in 1981 and is headquartered in The Woodlands, Texas.
Earnings Per Share
As for profitability, Tetra Technologies has a trailing twelve months EPS of $0.17.
PE Ratio
Tetra Technologies has a trailing twelve months price to earnings ratio of 35.29. Meaning, the purchaser of the share is investing $35.29 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.43%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 24.7%, now sitting on 604.13M for the twelve trailing months.
7. Vertex Pharmaceuticals (VRTX)
9.5% sales growth and 24.56% return on equity
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations. The company's pipeline includes VX-522, a CF mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial; and VX-864 for treatment of AAT deficiency, which is in Phase 2 clinical trial. In addition, it provides VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sell the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies or pharmacy chains, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Affinia Therapeutics; Arbor Biotechnologies, Inc.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Obsidian Therapeutics, Inc.; Verve Therapeutics; Skyhawk Therapeutics; and Ribometrix, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Earnings Per Share
As for profitability, Vertex Pharmaceuticals has a trailing twelve months EPS of $12.95.
PE Ratio
Vertex Pharmaceuticals has a trailing twelve months price to earnings ratio of 28.57. Meaning, the purchaser of the share is investing $28.57 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 24.56%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 13.5%, now sitting on 9.51B for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is a negative 0.7% and positive 2.7% for the next.
Sales Growth
Vertex Pharmaceuticals’s sales growth is 12.3% for the ongoing quarter and 9.5% for the next.
Previous days news about Vertex Pharmaceuticals(VRTX)
- According to Zacks on Friday, 13 October, "CRISPR Therapeutics, in partnership with large biotech Vertex Pharmaceuticals (VRTX Quick QuoteVRTX – Free Report) , has developed its lead pipeline candidate, exa-cel - an investigational ex-vivo CRISPR gene-edited therapy for treating sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT)."
8. BRT Realty Trust (BRT)
5.4% sales growth and 4.08% return on equity
BRT is a real estate investment trust that owns, operates and develops multi-family properties.
Earnings Per Share
As for profitability, BRT Realty Trust has a trailing twelve months EPS of $0.5.
PE Ratio
BRT Realty Trust has a trailing twelve months price to earnings ratio of 34.22. Meaning, the purchaser of the share is investing $34.22 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.08%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 29.6%, now sitting on 55.13M for the twelve trailing months.
Sales Growth
BRT Realty Trust’s sales growth is 25.3% for the present quarter and 5.4% for the next.
Earnings Before Interest, Taxes, Depreciation, and Amortization
BRT Realty Trust’s EBITDA is 32.88.
